253 related articles for article (PubMed ID: 2334898)
21. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK
Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946
[TBL] [Abstract][Full Text] [Related]
22. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
23. Factors associated with prognosis in human breast cancer. IV. Progesterone receptors and clinical factors.
Macías A; Pascual MR; Pérez R; Lage A
Neoplasma; 1983; 30(5):593-601. PubMed ID: 6656963
[TBL] [Abstract][Full Text] [Related]
24. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
[TBL] [Abstract][Full Text] [Related]
25. Estrogen receptor status in breast cancer.
Wright CJ
Can J Surg; 1980 Jul; 23(4):316-7. PubMed ID: 7417890
[TBL] [Abstract][Full Text] [Related]
26. Variations in steroid receptor status with disease stage in breast cancer.
Stebbings WS; Anderson E; Puddefoot JR; Vinson GP; Gilmore OJ; Plowman PN
Eur J Surg Oncol; 1989 Aug; 15(4):322-7. PubMed ID: 2759250
[TBL] [Abstract][Full Text] [Related]
27. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
28. [Steroid hormone receptors in breast cancer].
Nomura Y
Rinsho Byori; 1990 Jan; 38(1):26-30. PubMed ID: 2308219
[TBL] [Abstract][Full Text] [Related]
29. [Comparative study of single-point method and multipoint method in the measurement of estrogen receptor and progesterone receptor in breast cancer].
Shen XQ
Zhonghua Zhong Liu Za Zhi; 1992 Mar; 14(2):112-5. PubMed ID: 1618078
[TBL] [Abstract][Full Text] [Related]
30. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.
Dowsett M; Cuzick J; Wale C; Howell T; Houghton J; Baum M
J Clin Oncol; 2005 Oct; 23(30):7512-7. PubMed ID: 16234518
[TBL] [Abstract][Full Text] [Related]
31. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
[TBL] [Abstract][Full Text] [Related]
32. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
Chang J; Powles TJ; Allred DC; Ashley SE; Makris A; Gregory RK; Osborne CK; Dowsett M
Clin Cancer Res; 2000 Feb; 6(2):616-21. PubMed ID: 10690547
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers.
Koenders PG; Beex LV; Geurts-Moespot A; Heuvel JJ; Kienhuis CB; Benraad TJ
Cancer Res; 1991 Sep; 51(17):4544-8. PubMed ID: 1873798
[TBL] [Abstract][Full Text] [Related]
34. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
35. Thymidine labeling index and estrogen receptor level in 64 human breast cancers.
Gioanni J; Farges MF; Lalanne CM; Francoual M; Namer M
Biomedicine; 1979 Dec; 31(8):239-43. PubMed ID: 534681
[TBL] [Abstract][Full Text] [Related]
36. [Cancer of the breast and the receptor status].
Buonomo O; Serao A; Muggianu A; Guglielmelli E; Davoli E; Amori A
G Chir; 1991 Apr; 12(4):274-7. PubMed ID: 1911078
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status.
Fernández-Morales LA; Seguí MA; Andreu X; Dalmau E; Sáez A; Pericay C; Santos C; Montesinos J; Gallardo E; Arcusa A; Saigí E
Clin Breast Cancer; 2007 Apr; 7(7):559-64. PubMed ID: 17509165
[TBL] [Abstract][Full Text] [Related]
38. [A case of advanced breast cancer with multiple organ metastases successfully treated by tamoxifen].
Shiba E; Kobayashi T; Takeda T; Miya A; Kawano I; Takai S; Mori T
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2255-8. PubMed ID: 1444494
[TBL] [Abstract][Full Text] [Related]
39. The prognostic significance of single hormone receptor positive metastatic breast cancer: an analysis of three randomised phase III trials of aromatase inhibitors.
Stuart-Harris R; Shadbolt B; Palmqvist C; Chaudri Ross HA
Breast; 2009 Dec; 18(6):351-5. PubMed ID: 19836952
[TBL] [Abstract][Full Text] [Related]
40. Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy.
Silvestrini R; Daidone MG; Mastore M; Di Fronzo G; Coradini D; Boracchi P; Squicciarini P; Salvadori B; Veronesi U
J Clin Oncol; 1993 Jun; 11(6):1150-5. PubMed ID: 8501501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
